Dr. Angela Smith discusses FDA approval of Jelmyto for low-grade UTUC

episode

Urology Times Podcasts not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Could sofa theory help you find your ideal partner? 4 min · 23 Sep 2026 · Do you really know?

Behind The Scenes At Vogue World Milano 28 min · 23 Sep 2026 · The Run-Through with Vogue

Is end-to-end encryption really secure? 4 min · 23 Sep 2026 · Do you really know?

Do tongue scrapers actually help with bad breath? 5 min · 23 Sep 2026 · Do you really know?

Lab Notes: Have we found dark matter? 10 min · 23 Sep 2026 · The Science Show

Is it cool to have no friends? 26 min · 23 Sep 2026 · Today in Focus

Report any issue

Source

Recorded06 Jul 2020

Publisheraudioboom.com ↗

Handlerec:11143663

Show notes

This is episode's guest is Dr. Angela B. Smith, Co-director of the Multidisciplinary Genitourinary Oncology Service at the N.C. Cancer Hospital; Director of Urologic Oncology in the UNC Department of Urology; and Associate Professor of Urology at UNC School of Medicine. A member of the study advisory committee for UroGen Pharma, Smith discusses the recent FDA approval of Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in